News articles about Mylan (NASDAQ:MYL) have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mylan earned a coverage optimism score of -1.83 on their scale. InfoTrie also assigned news stories about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Mylan’s ranking:

A number of research analysts have recently weighed in on the company. Zacks Investment Research upgraded Mylan from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 30th. Evercore ISI reiterated a “buy” rating on shares of Mylan in a research report on Friday, August 9th. UBS Group dropped their price objective on Mylan to $23.00 and set a “neutral” rating for the company in a research report on Tuesday, May 28th. Royal Bank of Canada dropped their price objective on Mylan to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $34.50 price objective on shares of Mylan in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the stock. Mylan currently has an average rating of “Buy” and an average target price of $30.43.

READ  Greedfall review — A novel RPG with grand ambitions that stumbles

Shares of NASDAQ MYL traded down $0.70 during midday trading on Friday, hitting $18.34. The stock had a trading volume of 5,126,200 shares, compared to its average volume of 6,910,375. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 4.00, a PEG ratio of 0.90 and a beta of 1.77. Mylan has a 1-year low of $16.63 and a 1-year high of $39.59. The company has a quick ratio of 0.77, a current ratio of 1.37 and a debt-to-equity ratio of 1.15. The company has a fifty day moving average price of $19.03 and a 200 day moving average price of $23.24.

Mylan (NASDAQ:MYL) last released its quarterly earnings data on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. The business had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The company’s revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 EPS. On average, research analysts forecast that Mylan will post 4.3 EPS for the current year.

In other Mylan news, Director Sjoerd S. Vollebregt acquired 10,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were bought at an average cost of $19.11 per share, for a total transaction of $191,100.00. Following the acquisition, the director now directly owns 18,258 shares of the company’s stock, valued at $348,910.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Melina E. Higgins acquired 20,000 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were acquired at an average price of $17.68 per share, for a total transaction of $353,600.00. Following the completion of the acquisition, the director now directly owns 33,120 shares in the company, valued at $585,561.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,859 shares of company stock worth $1,628,752 over the last three months. 0.81% of the stock is currently owned by corporate insiders.

READ  Can Strong Memory Aid Lam Research (LRCX) in Q1 Earnings?

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Story: Different Options Trading Strategies



Receive News & Ratings for Mylan Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here